title: Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.
abstract: A patient with ataxia telangiectasia was treated with recombinant interleukin-2 (rIL-2) and the resulting immunological effects evaluated. The patient lacked IL-2 production, and immunoglobulin synthesis was also impaired. Treatment with IL-2 selectively increased serum IgM without any significant side effects. Therapy also restored B-cell function in vitro. IgM production as well as the proliferative response to Staphylococcus aureus strain Cowan I. These results suggest that IL-2 treatment may correct both T-cell and B-cell defects.
authors.affiliation: Third Department of Internal Medicine, Osaka University Hospital, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Doi
authors.forename: O
authors.initials: O
authors.lastname: Saiki
authors.forename: T
authors.initials: T
authors.lastname: Hara
authors.forename: T
authors.initials: T
authors.lastname: Sugita
authors.forename: K
authors.initials: K
authors.lastname: Ha-Kawa
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: S
authors.initials: S
authors.lastname: Negoro
authors.forename: H
authors.initials: H
authors.lastname: Yabuuchi
authors.forename: S
authors.initials: S
authors.lastname: Kishimoto
mesh_terms: D000293:Adolescent; D001260:Ataxia Telangiectasia / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis*; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D008297:Male
chemical_list: D007075:Immunoglobulin M; D007376:Interleukin-2